Baxter International Inc. has appointed Andrew Hider as its new president and chief executive officer (CEO), effective no later than September 3, 2025. Hider, who has been serving as the CEO of ATS Corporation since 2017, has a track record of driving growth and achieving margin improvement. Under his leadership, ATS experienced significant growth, with adjusted revenues nearly doubling over a five-year period, representing a low-to-mid teens compound annual growth rate (CAGR) and similar adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) CAGR over the same period.
During Hider's tenure, ATS's stock price has more than tripled on the TSX, outperforming major indices over the same period. ATS, a global, diversified company with a broad scale and range of capabilities, operates 65+ manufacturing facilities globally. Hider has been lauded for his operational excellence, disciplined execution, and innovation, and is recognized for his ability to manage complex operations and generate value for shareholders while maintaining a customer-centric focus.
Hider expressed his enthusiasm for joining Baxter, citing the company's mission-driven culture and strong legacy of creating medically essential products that address patients' and customers' most pressing needs. He looks forward to partnering with the Board and colleagues to accelerate innovation, enhance performance, and redefine healthcare delivery while driving sustainable, long-term growth.
Andrew Hider brings 25 years of cross-industry experience and global expertise, a growth orientation, and an operationally focused, people-centric leadership approach to Baxter. Before joining ATS, he served as president and CEO of the Taylor Made Group, LLC, and held various leadership roles at Danaher Corporation and General Electric Co. Hider also serves as a member of the board of Tennant Company.
Baxter International Inc. is a global medtech leader with approximately 38,000 team members, dedicated to its enduring mission of saving and sustaining lives. The company provides essential solutions in the hospital, physician's office, and other sites of care, with a portfolio of connected solutions, medical devices, and advanced injectable technologies.
The market has reacted to these announcements by moving the company's shares -4.26% to a price of $29.69. For the full picture, make sure to review BAXTER INTERNATIONAL INC's 8-K report.
